NEW YORK (GenomeWeb) – Biocept reported after the close of the market Thursday that its third quarter revenues rose sharply year over year on increased test volume.

The San Diego-based maker of cancer biomarker assays reported total revenues of $164,856 for the three months ended Sept. 30, up from $10,274 for the third quarter of 2014. It said that it accessioned 482 commercial cases during the quarter, nearly five times the 96 commercial cases for the third quarter of 2014.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.